Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Immunisation, Metastasis, Neoplasm, Neoplasm malignant, SARS-CoV-2 test
Clinical narrative: Cancer had been slow growing over 9 years; Metastasis to bone; tumor growth; booster; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 53 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm right, administration date 15Oct2021 14:00 (Lot number: 301458A) at the age of 53 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Neuroendocrine cancer or pancreases with liver mets" (unspecified if ongoing), notes: Other medical history: Neuroendocrine cancer or pancreases with liver mets. Concomitant medication(s) included: OCTREOTIDE taken for neoplasm malignant. Past drug history included: Ketamine, reaction(s): "Known allergies: Ketamine", notes: Known allergies: Ketamine. Vaccination history included: Bnt162b2 (prev dose product: COVID 19, prev dose brand: Pfizer, prev dose brand unknown: False, prev dose lot number: EN6201, prev dose lot unknown: False, prev dose administrator route: Intramuscular, prev dose administration date: 12Feb2021, prev dose administration time: 01:00 PM, prev dose dose number: 2, prev dose vaccine location: Right arm), administration date: 12Feb2021, when the patient was 53 years old, for Covid-19 Immunization; Bnt162b2 (prev dose brand: Pfizer, prev dose brand unknown: False, prev dose lot number: EL8982, prev dose lot unknown: False, prev dose administrator route: Intramuscular, prev dose administration date: 21Jan2021, prev dose administration time: 01:00 PM, prev dose number: 1, prev dose vaccine location: Right arm), administration date: 21Jan2021, when the patient was 53 years old, for Covid-19 Immunization. The following information was reported: IMMUNISATION (life threatening) with onset 15Oct2021 14:00, outcome "unknown", described as "booster"; NEOPLASM MALIGNANT (medically significant, life threatening) with onset 15Dec2021 14:00, outcome "not recovered", described as "Cancer had been slow growing over 9 years"; NEOPLASM (life threatening) with onset 15Dec2021 14:00, outcome "not recovered", described as "tumor growth"; METASTASIS (medically significant, life threatening) with onset 15Dec2021 14:00, outcome "not recovered", described as "Metastasis to bone". The events "booster", "cancer had been slow growing over 9 years", "tumor growth" and "metastasis to bone" were evaluated at the physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (27Dec2021) negative. Therapeutic measures were taken as a result of neoplasm malignant, neoplasm, metastasis. Ae treatment: Emergency radiation and biopsy.  Clinical information: Patient was doing well just finished PRRT liquid radiation treatments. took booster 2 months after. Cancer had been slow growing over 9 years. In December, 2 months after booster had major tumor growth and metastasis to bone. No other vaccine in four weeks. No covid prior vaccination.; Sender's Comments: Based on the information provided the events neoplasm malignant, neoplasm and metastasis were assessed as unrelated to the suspect drug bnt162b2 and considered as likely due to the underlying medical condition. Case will be reassessed if any new information is available.